• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Practical Use of RBX2660 for the Prevention of Recurrent Clostridioides difficile Infection.

作者信息

Feuerstadt Paul, Allegretti Jessica R, Khanna Sahil

机构信息

Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

PACT-Gastroenterology Center, Hamden, Connecticut, USA.

出版信息

Am J Gastroenterol. 2023 Aug 1;118(8):1303-1306. doi: 10.14309/ajg.0000000000002195. Epub 2023 Jan 25.

DOI:10.14309/ajg.0000000000002195
PMID:36695753
Abstract
摘要

相似文献

1
Practical Use of RBX2660 for the Prevention of Recurrent Clostridioides difficile Infection.RBX2660在预防艰难梭菌反复感染中的实际应用
Am J Gastroenterol. 2023 Aug 1;118(8):1303-1306. doi: 10.14309/ajg.0000000000002195. Epub 2023 Jan 25.
2
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.RBX2660 在 PUNCH CD3 中的疗效和安全性：一项 III 期、随机、双盲、安慰剂对照试验，采用贝叶斯主要分析预防复发性艰难梭菌感染。
Drugs. 2022 Oct;82(15):1527-1538. doi: 10.1007/s40265-022-01797-x. Epub 2022 Oct 26.
3
A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent infection.RBX2660 活生物治疗产品概述及其在预防复发感染中的作用。
Expert Rev Anti Infect Ther. 2023 Mar;21(3):243-253. doi: 10.1080/14787210.2023.2171986. Epub 2023 Feb 9.
4
The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.基于微生物群的疗法在艰难梭菌感染中的作用：RBX2660的持久长期结果
Infect Dis Ther. 2023 Jan;12(1):1-7. doi: 10.1007/s40121-022-00714-9. Epub 2022 Nov 7.
5
Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.RBX2660的2b期随机、安慰剂对照临床试验的最终结果：一种用于预防艰难梭菌反复感染的基于微生物群的药物。
Infect Dis Ther. 2023 Feb;12(2):703-709. doi: 10.1007/s40121-022-00744-3. Epub 2022 Dec 21.
6
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.RBX2660 治疗后艰难梭菌感染复发和微生物组恢复的持久减少：一项开放标签 2 期临床试验的结果。
BMC Infect Dis. 2022 Mar 12;22(1):245. doi: 10.1186/s12879-022-07256-y.
7
Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Infection in Older Adults With Underlying Comorbidities.基于微生物群的活体生物疗法RBX2660用于降低患有基础合并症的老年人复发性感染的发生率。
Open Forum Infect Dis. 2022 Dec 30;10(1):ofac703. doi: 10.1093/ofid/ofac703. eCollection 2023 Jan.
8
Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Infection.基于微生物群的研究性活生物疗法治疗复发性感染后的人粪便胆汁酸分析
Microorganisms. 2023 Jan 5;11(1):135. doi: 10.3390/microorganisms11010135.
9
Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic.RBX2660（一种研究性微生物群恢复疗法）2期试验中治疗反应者的细菌微生物群组成和多样性恢复
Open Forum Infect Dis. 2019 Apr 11;6(4):ofz095. doi: 10.1093/ofid/ofz095. eCollection 2019 Apr.
10
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.对《RBX2660在PUNCH CD3中的疗效和安全性：一项用于预防艰难梭菌反复感染的III期、随机、双盲、安慰剂对照试验及贝叶斯主要分析》的勘误
Drugs. 2022 Oct;82(15):1539. doi: 10.1007/s40265-022-01805-0.

引用本文的文献

1
What's New and What's Next in Fecal Microbiota Transplantation?粪便微生物群移植的新进展与未来方向？
Biologics. 2025 Aug 21;19:481-496. doi: 10.2147/BTT.S486372. eCollection 2025.
2
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.PUNCH CD3 - OLS：一项3期前瞻性观察队列研究，旨在评估粪便微生物群活菌制剂（REBYOTA）在复发性艰难梭菌感染成人患者中的安全性和有效性。
Clin Infect Dis. 2025 Feb 5;80(1):43-51. doi: 10.1093/cid/ciae437.
3
Bacterial therapies at the interface of synthetic biology and nanomedicine.
合成生物学与纳米医学交叉领域的细菌疗法。
Nat Rev Bioeng. 2024 Feb;2(2):120-135. doi: 10.1038/s44222-023-00119-4. Epub 2023 Oct 10.
4
Microbiota restoration therapies for recurrent infection reach an important new milestone.用于复发性感染的微生物群恢复疗法达到了一个重要的新里程碑。
Therap Adv Gastroenterol. 2024 May 24;17:17562848241253089. doi: 10.1177/17562848241253089. eCollection 2024.
5
Alternative therapeutic strategies to treat antibiotic-resistant pathogens.治疗抗生素耐药病原体的替代治疗策略。
Nat Rev Microbiol. 2024 May;22(5):262-275. doi: 10.1038/s41579-023-00993-0. Epub 2023 Dec 11.